As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
|Articles|April 26, 2016
Disease Interception and the US National Cancer Moonshot
Author(s)DIA
April 26, 2016.
Advertisement
In the US, patients, caregivers and advocates, drug developers and the FDA have moved towards a patient-centered approach to drug development. The National Cancer Moonshot, a task force led by Vice President Joseph Biden, includes this patient-centric strategy in its agenda: Seeking to facilitate collaborations with researchers, doctors, philanthropies, patients, patient advocates, and biotechnology and pharmaceutical companies to accelerate the early detection and treatment of cancer, its goal is a decade’s worth of advances in five years.
Advertisement
Related to this article
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
4
Viatris Acquires Pacira BioSciences for $1.65 Billion
5